recombinant influenza vaccine
Trade name: Flublok
Vaccineexperimental
Clinical trial activity
3 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
1
Earliest trial started Jul 1, 2019 (NCT03965195)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant influenza vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07291635 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2026 | Aramis Biotechnologies Inc., McGill University |
| NCT06695130 | Phase 1/Phase 2 (Phase 2) | Nov 18, 2024 | Sanofi |
| NCT03965195 | Phase 4 | Jul 1, 2019 | Brown University, Case Western Reserve University, Insight Therapeutics, LLC, Sanofi-Aventis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aramis Biotechnologies Inc. | For profit | 1 | 1 | 1 | 2026 |
| Brown University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Case Western Reserve University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Insight Therapeutics, LLC | For profit | 1 | 1 | 1 | 2019 |
| McGill University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Sanofi | For profit | 1 | 1 | 1 | 2024 |
| Sanofi-Aventis | For profit | 1 | 0 | 1 | 2019 |
7 organizations
Page 1 / 1